Heron Therapeutics (HRTX) Equity Average: 2011-2025
Historic Equity Average for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to -$6.2 million.
- Heron Therapeutics' Equity Average rose 84.13% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.2 million, marking a year-over-year increase of 84.13%. This contributed to the annual value of -$33.8 million for FY2024, which is 231.47% down from last year.
- Heron Therapeutics' Equity Average amounted to -$6.2 million in Q3 2025, which was up 77.79% from -$27.9 million recorded in Q2 2025.
- Heron Therapeutics' Equity Average's 5-year high stood at $216.4 million during Q1 2021, with a 5-year trough of -$39.0 million in Q3 2024.
- Over the past 3 years, Heron Therapeutics' median Equity Average value was -$31.1 million (recorded in 2025), while the average stood at -$27.2 million.
- Its Equity Average has fluctuated over the past 5 years, first plummeted by 9,493.56% in 2023, then spiked by 84.13% in 2025.
- Heron Therapeutics' Equity Average (Quarterly) stood at $98.2 million in 2021, then slumped by 81.66% to $18.0 million in 2022, then tumbled by 271.45% to -$30.9 million in 2023, then dropped by 19.26% to -$36.8 million in 2024, then surged by 84.13% to -$6.2 million in 2025.
- Its Equity Average was -$6.2 million in Q3 2025, compared to -$27.9 million in Q2 2025 and -$31.1 million in Q1 2025.